ClinicalTrials.gg
Status unknownNCT05638009EPICUpdated Dec 15, 2022

The ECLA/PHRI Intervention in the Community Trial

An interventional study of Salt substitute 66%33% and Salt substitute 33%/66% in Hypertension, sponsored by Estudios Clínicos Latino América. Status unknown at 1 site in Argentina. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-15.

Sponsored by Estudios Clínicos Latino América · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,490
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 74 studies in Hypertension with a site in Argentina — 12 open to participants now, 18 under way, 9 of them phase 3. Hypertension · Argentina.

Planned enrollment
8th of 68
2,490 · median 674
Started
2022
with 2 others
No phase
13 of 74
3 open now
Registered
53rd of 74
by date

Among the 74 studies in Hypertension with a site in Argentina, this one is the 8th largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2022, is one of 13 with no phase, and was the 53rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

12 of the 74 studies in Hypertension with a site in Argentina are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Hypertension with a site in Argentina, or all of them as a file.
02

Study summary

EPIC is a cluster-randomized, double-blind trial to evaluate the effect of two potassium-enriched salt substitute preparations (one available in the Argentine market and one derived from it), compared to regular salt on systolic blood pressure in subjects ≥ 18 and ≤ 90 years old from Rosario department households in Santa Fe Province, Argentina.

Read the detailed description

The effect of reduced sodium salt preparations has been evaluated in clinical studies (observational and randomized clinical trials) and in meta-analyses, and although a reduction in blood pressure was observed, they have particular characteristics that make them difficult to extrapolate their results to Western populations.

In one of these trials, conducted in rural Indian hypertensive patients, the use of a salt substitute of 75% sodium chloride and 25% potassium chloride showed a significant reduction of systolic blood pressure with a mean difference of -4.58 mmHg in 3 months from baseline to the end of the trial.

Recently, a large cluster-randomized trial conducted in 600 villages in rural areas of five provinces of China (SSaSS trial) among patients with a history of stroke or 60 years of age or elder with elevated blood pressure showed that stroke rates, major cardiovascular events and death from any cause were significantly lower with a salt substitute than with regular salt. The salt substitute used in this trial had 1/3 less sodium than regular salt and substantially more potassium. Therefore, the salt substitute led to an 8% less sodium intake but a 50% higher intake in potassium. This suggests that the greatest impact of salt substitution in this RCT may have been due to an increase in potassium intake rather than the modest decrease in sodium intake that was associated with an average reduction of 2.65 mmHg for SBP (-4.32 to -0.97) and +0.30 mmHg (-0.72 to +1.32) for DBP. In addition, the mean sodium intake in the studied population in this trial was approximately 4.2 gr/d, which is higher than the global average worldwide sodium consumption of 3.9 gr/d. In contrast, potassium intake was lower than the average global potassium intake. Therefore, several considerations that limit the applicability to other populations remain unresolved. The sodium intake of the Chinese rural population is higher than in many other countries, while the potassium intake is relatively low. In addition, in many countries commercially available foods may have added sodium chloride for preservation and thus increase the amount of sodium to the diet. Therefore, the use of salt substitutes would not fully account for salt intake in most cases. Finally, Chinese social and environmental features may be somewhat different to most western countries.

EPIC's investigators stated the hypothesis that salt substitutes could lower systolic blood pressure in a dose-response mode. Therefore, they propose to conduct a randomized cluster trial to evaluate the effect of consuming two doses enriched potassium salt substitutes preparations compared to regular salt intake on systolic blood pressure in individuals from Rosario department.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Sodium Chloride
  • Dietary
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects ≥ 18 and ≤ 90 years old will be included, with no specific clinical conditions from households that meets the following criteria:

  • The household must be composed of at least 2 individuals
  • At least 1 of the individuals included must be over 40 years of age
  • The household must be located in Rosario department, Santa Fe province, Argentina

Exclusion criteria

Exclusion Criteria:

Households will be excluded if a any household member has a at least one of the following to the salt substitute used in the trial:

  • use of a potassium-sparing diuretic
  • use of a potassium supplement
  • known history of hyperkalemia
  • use of salt reduced in sodium and enriched in potassium by medical indication
  • do not consume any type of salt for medical indication
  • known primary or secondary hyperaldosteronism
  • known severe kidney disease (routine biochemical measurement of kidney function will not be performed in household members not included in the study).
  • Pregnancy or lactation
  • Evidence of hyperkalemia and/or a (calculated through the formula \<30 ml/min/1.73m2) in baseline blood laboratory. For those participants who consent to be tested, blood sample will be used. For those participant who has a laboratory test performed with those biomarkers in the past 6 months those results will be considered
  • Households in which any of the study participants consume more than 50% of their meals prepared outside their home will also be excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,490 participants (estimated)

Study arms

  • No intervention
    Control

    regular salt (99% sodium chloride)

  • Experimental
    Salt substitute 1

    Salt substitute 1 is a potassium-enriched salt substitute composed of 66% potassium chloride and 33% sodium chloride

    Dietary Supplement: Salt substitute 66%33%

  • Experimental
    Salt substitute 2

    Salt substitute 2 is a potassium-enriched salt substitute composed of 33% potassium chloride and 66% sodium chloride

    Dietary Supplement: Salt substitute 33%/66%

Interventions

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure at day 120

    Systolic Blood Pressure will be measured by a standardized automated device

    Time frame: 120 days

Secondary outcomes

  1. Hyperkalemia

    Evidence of Hyperkalemia is determined by clinical suspicion or biochemical value defined as a serum potassium value above 5.5 mmol/l (in case it is measured) during the follow up.

    Time frame: 120 days

  2. Salt substitutes acceptance and incorporation into the diet

    Salt substitutes acceptance and incorporation into the diet will be measured through a questionnaire administrated at 30 days and follow-up. The questionnaire includes the following questions: How many days in the last week did you use study salt? If you were meant to use the study salt in the last week but did not use it every day, what is the reason? If you use the study salt in the last week: How did you use it? How many meals did you use the study salt during the day? Did you enjoy the taste? (1 = disliked a lot; 10 = liked a lot)

    Time frame: 120 days

  3. Diastolic Blood Pressure at day 120

    Diastolic Blood Pressure will be measured by a standardized automated device

    Time frame: 120 days

  4. Mean arterial pressure (MAP) at day 120

    Systolic and Diastolic Blood Pressure will be measured by a standardized automated device in order to compute MAP

    Time frame: 120 days

07

Study locations

1 of 1 sites recruiting
  • IIC-Instituto de Investigaciones Clínicas
    Rosario, Santa Fe 2000, Argentina
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Apr 2023, 5 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2022
First posted
Dec 6, 2022
StartActual
Nov 14, 2022
Primary completionEst.
Apr 14, 2023
CompletionEst.
Jun 30, 2023
Last update
Dec 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05638009
Lead sponsor
Estudios Clínicos Latino América
Responsible party
Sponsor
First posted
Dec 6, 2022
Start date
Nov 14, 2022
Primary completion
Apr 14, 2023 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Dec 15, 2022

Study contacts

María Luz Diaz, MD
Contact
marialuzdiaz02@gmail.com
+54 9 341605-3295
Juan Manuel Dominguez, MD
Contact
jdominguez@eclainternational.org
+54 9 341210-6243
María Luz Diaz, MD
principal investigator · ECLA- Estudios Clínicos Latino América

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salt substitute

Start the discussion